STL Index for: Tretinoin
Clascoterone 1% cream represents a novel and promising therapeutic agent in the management of acne vulgaris for individuals ≥12 years of age. Notably, this topical agent was not observed to have significant systemic effects seen with systemic anti-androgenic agents.
The update covers: Tazarotene lotion, 0.045% - Arazlo™ (Bausch Health), Anifrolumab-fnia IV use - Saphnelo™ (AstraZeneca), Immune globulin intravenous (human) 10% - Octagam® 10% (Octapharma), Odevixibat capsule - Bylvay™ (Albireo Pharma) and other treatments
This review details the rosacea phenotype approach to diagnosis and classification, and summarizes current evidence-based treatment recommendations for individual features.
Update on PrabotulinumtoxinA, Tretinoin 0.05% lotion, Cemiplimab-rwlc, Autologous fibroblast gene therapy, Oral JAK3 inhibitor, Halobetasol propionate 0.01% lotion, Sarecycline hydrochloride tablets and HPV 9-valent vaccine.
The focus of this review is to delve deeper into the use of Biacna® Gel, a fixed-dose clindamycin/tretinoin combination product, for the treatment of acne.
Truncal acne refers to AV affecting the chest and/or back, a common presentation in acne patients. This article offers guidance in clinical differentiation of truncal acne from other acneiform diseases and provides management recommendations.
Physicians will be particularly reassured if the suggested guidelines are supported by scientific evidence. This new Canadian clinical guideline for the treatment of acne was developed taking into account new data published up to March 2015, as well as expert opinion and clinical experience.
Treatment of PIH and melasma is challenging. There are no singular therapies that are efficacious on its own. Management, sun protection, topical lightening therapy and other treatment modalities are considered in this discussion on these growing concerns.
Acne vulgaris is a multifactorial disease characterized by different types of lesions at various stages of development. Treatment options, such as light based therapy and systemic therapy, as well as CIS-Isotretinoin (Epuris™) that increases absorption are discussed as well as patient adherence.
Acne vulgaris is a multifactorial disease characterized by different types of lesions at various stages of development. The most frequently used therapeutic agents for acne are topical. This article focuses on the role of vehicles and advancements in this area.
Acne is among the most common dermatological disorders seen by dermatologists, affecting approximately 85% of people between the ages of 12 and 24 years. The use of adjunctive cleansers and moisturizers can help mitigate treatment side effects and subsequently enhance therapeutic efficacy.
Acne vulgaris (AV) is among the most common dermatological disorders seen by dermatologists. Emerging evidence suggests that acne is associated with epidermal barrier impairments, and this article reviews the role of moisturizing, sun protection, and patient specific skincare advice for acne patients.
Rosacea is a common chronic skin disorder that has significant impact on the quality of life of affected individuals. Research interest has led to the development of other emerging therapies including topical ivermectin, brimonidine and oxymetazoline that hold promise for patients suffering from this condition.
Acne vulgaris is the most common skin disorder affecting children and young adults in North America. This article discusses combination therapy, and simplifying treatment plans in order to increase patient adherence, which is often a critical problem in treating acne.
Acne vulgaris is a common chronic inflammatory cutaneous disease involving the pilosebaceous unit. This article discusses the multifactorial nature of acne pathophysiology, therapeutics, and mechanism of action.
Acne vulgaris is a chronic inflammatory cutaneous disease involving the pilosebaceous unit. This article discusses pathophysiology, sebum production, keratinization, and the role of P.acnes in acne formation.
The development of topical cosmetic anti-aging products is becoming increasingly sophisticated. This article reviews trials that look at the efficacy of cosmetic (OTC) products against prescription products.
This article delves into appropriate use of topical therapies for acne treatment. Appropriate agent selection, tolerance, adherence, follow-up, and considerations like complexity of treatment are discussed.
Solid organ transplant recipients have an increased incidence of skin cancer, resulting in significant morbidity and mortality post-transplantation. This article studies systemic retinoids, and other chemopreventative agents for high risk patients.
Topical treatment is the mainstay for mild acne, and adjunctive to oral or hormonal therapy for moderate acne. This article explores recent formulary advances and offers clinical strategies that can encourage adherence and improve treatment outcomes.
A vast spectrum of topical anti-acne agents has emerged in response to new insights that have been gained through the understanding of disease pathophysiology and the need for clinicians to adopt an individualized therapeutic approach.
The multifactorial nature of acne vulgaris often requires a combination of topical and/or oral agents for successful management. Common challenges of this multipronged approach include the potential development of skin irritation, which results in nonadherence, as well as concern over bacterial resistance.
As baby boomers get older, they have shown an increasing interest in maintaining a youthful appearance. As a result, there has been a corresponding increase in topical antiaging formulations, which are commonly referred to as cosmeceuticals.
Topical retinoids are the cornerstone of acne therapy and they can be used across the entire spectrum of acne severity. Selecting the most suitable retinoid formulation, as well as dispensing proper advice in terms of drug application, can improve patient compliance.
Hyperpigmentation disorders of the skin are common and can be the source of significant psychosocial distress for patients. Topical applications are the mainstay of treatment and include phenols, retinoids, corticosteroids, and their combinations.
Although the developing fetus was once considered protected from the outside world, we now know that it can potentially be affected by any medication given to the mother. Therapeutic options available for these patients will be discussed.
Disorders of hyperpigmentation are difficult to treat, particularly in dark-skinned individuals. The goal is to reduce the hyperpigmentation without causing undesirable hypopigmentation or irritation in the surrounding normally pigmented skin. The psychosocial impact caused by these disorders must be considered.
Tazarotene (Tazorac®, Allergan) has been shown to be effective in reducing the effects of photoaging in short term studies. To determine its effectiveness in the longer term, a 24-week multicenter, double-blind, randomized, vehicle controlled intervention study of 563 patients with facial photodamage was carried out.
Hydroquinone has been successfully used to treat hyperpigmentation for many years. Recently, new formulations containing hydroquinone have become available, including Lustra® and Lustra-AF®. These products also contain glycolic acid 2%, an active antioxidant system, and moisturizers.
Psoriasis, acne vulgaris and photoaging are common conditions. Tazarotene is a pro-drug of tazarotenic acid, a receptor-selective retinoid, which has shown efficacy in the treatment of these disorders. In the treatment of acne vulgaris, it has greater comedolytic activity than the currently available topical retinoids.
Topical acne treatment can positively benefit patients with acne. This review summarizes clinical and prescribing information on currently available topical agents. The efficacy of the medications included in this report is supported by properly designed randomized clinical trials.
12Page 1 of 2